Investor's Business Daily on MSN4h
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug from China's LaNova Medicines.Please watch the video at Investors.com - ...
Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
FiercePharma1d
BMS, Merck, Amgen and more must look to M&A to offset looming patent lapses: Leerink
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Yahoo Finance9d
Merck Insiders Sold US$11m Of Shares Suggesting Hesitancy
Over the last year, we can see that the biggest insider sale was by the Executive VP & President of Merck Animal Health, Richard DeLuca, for US$4.6m worth of shares, at about US$105 per share.
Top 2 pharma stocks to buy amid surge in deadly fungi
Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...
Merck: An Undervalued Dividend Machine
Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...
Merck sees Gardasil China woes carrying into 2025
Merck & Co said on Thursday that weak sales of Gardasil in China are likely to carry over into 2025 as the vaccine's distributor there reduces inventories amid low demand, and the U.S. drugmaker's ...